Faster Approval Process Contributing to Biotech Industry's Success in 2012

The Paragon Report Provides Stock Research on AEterna Zentaris and Galena Biopharma

Marketwired

NEW YORK, NY--(Marketwire - Sep 12, 2012) - Despite concerns of a global economic slowdown the Biotech Industry has impressed investors with strong gains in 2012. Patent expirations, favorable legislation, and a faster review process have been some of the contributing factors for the industry's current boom. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on AEterna Zentaris Inc. (NASDAQ: AEZS) and Galena Biopharma Inc. (NASDAQ: GALE).

Access to the full company reports can be found at:
www.ParagonReport.com/AEZS
www.ParagonReport.com/GALE

The Food and Drug Administration Safety and Innovation Act (FDASIA) was signed into law on July 9, 2012 by President Obama. The law allows the FDA to collect "user fees" to help fund reviews of innovator drugs, medical devices, generic drugs and biosimilars.

"The legislation will enhance the development and review of innovative new therapies through increased transparency and scientific dialogue, advancements in regulatory science and strengthened post-market review. It will also increase the Food and Drug Administration's (FDA) access to external expertise to improve the drug review process," Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood said in a statement.

Paragon Report releases regular market updates on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.ParagonReport.com and get exclusive access to our numerous stock reports and industry newsletters.

Aeterna Zentaris is an oncology and endocrinology drug development company currently investigating treatments for various unmet medical needs. The Company's pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. The first patient was recently recruited for a Phase 2A trial with its ghrelin agonist, AEZS-130 in patients with cancer cachexia.

Galena Biopharma is focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using targeted biotherapeutics. The company on July 18, 2012 was issued a patent for their product candidate, NeuVax, a HER2/neu peptide vaccine. Shares of the company have more than tripled in 2012.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at:
http://www.paragonreport.com/disclaimer

View Comments